Bioverativ

Bioverativ Inc.
Company typeSubsidiary
Nasdaq: BIVV
IndustryBiotechnology
Founded2016; 8 years ago (2016)
(Spun off from Biogen)
Key people
John G. Cox (CEO)
[1]
ProductsAlprolix, Eloctate
Number of employees
400[2]
ParentSanofi
Websitesanofi.com

Bioverativ Inc. is an American multinational biotechnology company that specializes in the discovery, development, and delivery of therapies for the treatment of haemophilia.[3] Bioverativ competes with Baxalta (acquired by Shire Plc in 2016[4]), Pfizer and Novo Nordisk.[2] The company traded on the NASDAQ exchange under the ticker symbol BIVV until Sanofi completed its acquisition on March 8, 2018.

  1. ^ "Biogen Announces Additional Members of Management Team of Hemophilia Spin-off Company Bioverativ - Biogen Media". Archived from the original on 2016-12-29. Retrieved 2016-12-28.
  2. ^ a b "Biogen". SEC.gov. Retrieved 22 May 2024.
  3. ^ "Sanofi Agrees to Buy Biovia for $11.6BN". Industry News. Pharma Technology Focus (67). Net Resources International. January 22, 2018.
  4. ^ Farrell, Sean (January 2016). "Shire clinches $32bn takeover of Baxalta". The Guardian.